Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 155, Issue 4, 1997, Pages 1241-1246

  Weersink, Els J M ^a   Douma, Rob R ^a   Postma, Dirkje S ^a   Koëter, Gerard H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE;

ADULT; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; DRUG SCREENING; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030940103     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.155.4.9105061     Document Type: Article

References (33)

1. Martin, R. J., L. C. Cicutto, and R. D. Ballard. 1990. Factors related to the nocturnal worsening of asthma. Am. Rev. Respir. Dis. 143: 33-38.
2. Turner-Warwick, M. 1988. Epidemiology of nocturnal asthma. Am. J. Med. 85(Suppl. 1B):6-8.
3. Chhabra, S. K. 1995. An epidemiological investigation into nocturnal asthma. J. Asthma 32:147-150.
4. Wempe, J. B., E. P. Tammeling, D. S. Postma, B. Auffarth, J. P. Teengs, and G. H. Koëter. 1992. Effects of budesonide and bambuterol on circadian variation of airway responsiveness and nocturnal symptoms of asthma. J. Allergy Clin. Immunol. 90:349-357.
5. Pearlman, D. S., P. Chervinsky, C. LaForce, J. M. Seltzer, D. L. Southern, J. P. Kemp, R. J. Dockhorn, J. Grossman, R. F. Liddle, and S. W. Yancey. 1992. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N. Engl. J. Med. 327: 420-1425.
6. Lötfall, J., H. Lunde, A. Ullman, H. Törnqvist, and N. Svedmyr. 1992. Twelve months, treatment with inhaled salmeterol in asthmatic patients. Allergy 47:477-483.
7. Britton, M. G., J. S. Earnshaw, and J. B. D. Palmer. 1992. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur. Respir. J. 5:1062-1067.
8. Palmer, J. B. D., A. M. Stuart, G. L. Shepherd, and K. Viskum. 1992. Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease: a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms). Respir. Med. 86:409-417.
9. D'Alonzo, G. E., R. A. Nathan, S. Henochowicz, R. J. Morris, P. Ratner, and S. I. Rennard. 1995. Salmeterol xinofoate as maintenance therapy compared with albuterol in patients with asthma. J.A.M.A. 271:1412-1416.
10. Dahl, R., J. S. Earnshaw, and J. B. D. Palmer. 1991. Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. Eur. Respir. 4:1178-1184.
11. Fitzpatrick, M. F., T. Mackay, H. Driver, and N. J. Douglas. 1990. Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long-acting inhaled β2 agonist. B.M.J. 301:1365-1368.
12. Oosterhoff, Y., G. H. Koëter, J. G. R. de Monchy, and D. S. Postma. 1993. Circadian variation in airway responsiveness to methacholine, propranolol, and AMP in atopic asthmatic subjects. Am. Rev. Respir. Dis. 147(Suppl.):12-17.
13. Polosa, W. H. N. R., and M. K. Church. 1990. Adenosine bronchoconstriction in asthma: investigations into its possible mechanism of action. Br. J. Pharmacol. 30:89s-98s.
14. Björck, T., L. E. Gustafsson, and S. Dahlén. 1992. Isolated bronchi from asthmatics are hyperresponsiveness to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. Am. Rev. Respir. Dis. 145:1087-1091.
15. Rafferty, P., R. Beasley, P. Southgate, and S. T. Holgate. 1987. The role of histamine in allergen and adenosine-induced bronchoconstriction. Int. Arch. Allergy Appl. Immunol. 82:292-294.
16. Rafferty, P., R. Beasley, and S. T. Holgate. 1987. The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5′monophosphate in atopic asthma. Am. Rev. Respir. Dis. 136:369-373.
17. Polosa, R., H. Wai, N. Crimi, C. Vancheri, S. T. Holgate, M. K. Church, and A. Mistretta. 1995. Release of mast-cell-derived mediators after endobronchial adenosine challenge in asthma. Am. J. Respir. Crit. Care Med. 151:624-629.
18. Cockcroft, D. W., D. N. Killian, J. J. A. Mellon, and F. E. Hargreave. 1977. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin. Allergy 7:235-243.
19. Derom, E. Y., R. A. Pauwels, and M. E. Van der Straeten. 1992. The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours. J. Allergy Clin. Immunol. 89:811-815.
20. 2 agonist salmeterol in mild to moderate asthmatic patients. Thorax 48:1121-1124.
21. Rabe, K. F., R. Jörres, D. Nowak, N. Behr, and H. Magnussen. 1993. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am. Rev. Respir. Dis. 147:1436-1441.
22. Dahl, R., B. Pedersen, and B. Hägglöf. 1989. Nocturnal asthma: effect of treatment with oral sustained-release terbutaline, inhaled budesonide, and the two in combination. J. Allergy Clin. Immunol. 83: 811-815.
23. Ayres, J. G., E. D. Bateman, B. Lundback, and T. A. J. Harris. 1995. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. Eur. Respir. J. 8:579-586.
24. Greening, A. P., P. W. Ind, M. Northfield, and G. Shaw. 1994. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344:219-224.
25. Barnes, P. J., G. FitzGerald, M. Brown, and C. Dollery. 1980. Nocturnal asthma and changes in circulating epinephrine, histamine and cortisol. N. Engl. J. Med. 303:263-267.
26. Oosterhoff, Y., H. F. Kauffman, B. Rutgers, F. J. Zijlstra, G. H. Koëter, and D. S. Postma. 1995. Inflammatory cell number and mediators in bronchoalveolar lavage fluid and peripheral blood in subjects with asthma with increased nocturnal airway narrowing. J. Allergy Clin. Immunol. 96:219-229.
27. Barnes, P. J., and S. Pedersen. 1993. Efficacy and safety of inhaled corticosteroids in asthma. Am. Rev. Respir. Dis. 148:S1-S26.
28. Booth, H., P. V. Gardiner, C. Ward, A. Walls, D. J. Hendrick, and E. H. Walters. 1993. Effect of fluticasone propionate on airway inflammation as assessed by bronchoalveolar lavage (BAL). Eur. Respir. J. 6:584s.
29. Djukanovic, R., J. W. Wilson, K. M. Britten, S. J. Wilson, A. F. Walls, W. R. Roche, P. H. Howarth, and S. T. Holgate. 1992. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am. Rev. Respir. Dis. 145:669-674.
30. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J. Allergy Clin. Immunol. 90:32-42.
31. Butchers, P. R., C. J. Vardey, and M. Johnson. 1991. Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung. Br. J. Pharmacol. 104:672-676.
32. Roberts, J. A., P. Bradding, A. F. Walls, S. T. Holgate, and P. H. Howarth. 1992. The effect of salmeterol xinafoate therapy on lavage findings in asthma. Am. Rev. Respir. Dis. 145(Suppl.):A418.
33. Roberts, J. A., P. Bradding, A. F. Walls, K. M. Britten, S. J. Wilson, S. T. Holgate, and P. H. Howarth. 1992. The influence of salmeterol xinafoate on mucosal inflammation in asthma. Am. Rev. Respir. Dis. 145(Suppl.):A418.